000171213 001__ 171213
000171213 005__ 20260515163945.0
000171213 0247_ $$2doi$$a10.1002/hup.70046
000171213 0248_ $$2sideral$$a149293
000171213 037__ $$aART-2026-149293
000171213 041__ $$aeng
000171213 100__ $$aArqueros, María
000171213 245__ $$aInvestigating Hypo‐Egoic Features: Ayahuasca's Psychedelic Path Versus Meditation's Mindful Journey
000171213 260__ $$c2026
000171213 5203_ $$aObjective
‘Ego dissolution’ refers to a temporary state characterized by diminished self-referential processing, which leads to a breakdown of personal boundaries and an enhanced sense of unity with the environment. Both psychedelics, such as ayahuasca, and contemplative practices, like meditation, have been proposed as mechanisms for modulating the ego. While ayahuasca induces transient self-perception alterations, meditation promotes more sustained changes through cognitive and emotional regulation. This study examines whether ayahuasca consumption modulates the ego and compares its effects with those of meditation.
Methods
A total of 37 ayahuasca users and 137 meditators participated. We used the “Delusion of Me” (DoM) index, a unidimensional self-report measure comprising three domains: acceptance, decentering, and non-attachment. It could be considered closely related to the concept of self ‘as a content’ and may potentially serve as a measure of ego.
Results
Meditators exhibited significantly higher DoM scores than ayahuasca users. The quadratic regression did not show a cumulative effect, with no significant relationship found between the number of ayahuasca sessions and DoM scores.
Conclusions
Meditation practice correlated with higher DoM scores and cumulative practice showed a significant non-linear association with DoM. Conversely, repeated ayahuasca exposure demonstrated no evidence of a cumulative association in this sample.
000171213 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000171213 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000171213 700__ $$aSoler, Joaquim
000171213 700__ $$aCebolla, Ausiàs
000171213 700__ $$0(orcid)0000-0002-3797-4218$$aGarcia-Campayo, Javier$$uUniversidad de Zaragoza
000171213 700__ $$aDomínguez-Clavé, Elisabet
000171213 700__ $$aPascual, Juan C.
000171213 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000171213 773__ $$g41, 3 (2026), e70046 [6 pp.]$$pHum. psychopharmacol.$$tHUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL$$x0885-6222
000171213 8564_ $$s521211$$uhttps://zaguan.unizar.es/record/171213/files/texto_completo.pdf$$yVersión publicada$$zinfo:eu-repo/date/embargoEnd/2027-04-24
000171213 8564_ $$s2084832$$uhttps://zaguan.unizar.es/record/171213/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada$$zinfo:eu-repo/date/embargoEnd/2027-04-24
000171213 909CO $$ooai:zaguan.unizar.es:171213$$particulos$$pdriver
000171213 951__ $$a2026-05-15-14:55:12
000171213 980__ $$aARTICLE